China Aoxing Pharmaceutical Company has said that the China State Food & Drug Administration (SFDA) has granted the company the designated manufacturer status to produce Tilidine Tablets and Capsules, a highly regulated narcotic drug, in order to address significant unmet medical needs in cancer pain management in China.
Mr Liying Yang, Aoxing Vice President of R&D, commented, "SFDA's decision solidifies our leading position in narcotic drug business of China. For Tilidine, it sells multi-hundred million Euros per year as a generic in Europe under the aegis of a global top three pharmaceutical manufacturer. The company under SFDA regulations will have five-year exclusivity in the China market. Based on the regulations set forth by the China SFDA in this sector, currently there are only 13 pharmaceutical companies allowed to be in this business in China. More importantly, the agency designates only one-two drug companies to be involved in raw material, or active pharmaceutical ingredient (API) production for a particular narcotic drug, and only one-three companies in the area of associated finished doses of a single product.
Mr Zhenjiang Yue, Aoxing CEO, said: " We expect to launch this important and needed cancer pain medicine through Aoxing's integrated 500 person sales force in later 2008. Cancer pain management is a key component in oncology therapy, and becomes the top priority for terminal cancer patients. Cancer has become the first cause of death in China, estimated at 1.5 million victims per year. The number of victims is soaring especially in rural and western China as Western diet and lifestyle becomes prevalent. China's government and medical community are fully aware that China is woefully behind the rest of world in cancer pain treatment. For example, the consumption of morphine for pain per capita only amounts to 1/3 of other developing countries, more strikingly, almost 0.5% of developed countries. Our mission is to bring multiple effective therapeutic options, including Oxycodone, Tilidine and other promising narcotic pain medicines in our pipeline, to help approximately 20 million cancer patients in China."
China Aoxing Pharmaceutical Company is a pharmaceutical company in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain management products.